Amendments to the Claims:

Please cancel claims 1-35 without disclaimer or prejudice to applicants' right to pursue the subject matters of these claims in the future.

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-35. (Canceled)

36. (New) A method for the treatment of a fibrosis related pathology in a subject in need of such treatment comprising administering to the subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject.

37. (New) A method of claim 36 wherein the fibrosis related pathology is liver fibrosis.

38. (New) A method of claim 36 wherein the fibrosis related pathology is pulmonary fibrosis.

39. (New) A method of claim 36 wherein the fibrosis related pathology is cardiac fibrosis.

40. (New) A method of claim 36 wherein the fibrosis related pathology is kidney fibrosis.

41. (New) A method of claim 36 wherein the fibrosis related pathology is scarring.

42. (New) A method of claim 36 wherein the fibrosis related pathology is selected from nephropathy, chronic renal insufficiency, chronic renal failure and glomerulosclerosis.

43. (New) The method of claim 42 wherein the nephropathy is diabetic nephropathy.

44. (New) The method of claim 36 wherein the inhibitor is an antibody which binds specifically to HNOEL-iso polypeptide.

45. (New) The method of claim 36 wherein the inhibitor is an siRNA which is specific to HNOEL-iso polynucleotide.

46. (New) The method of claim 36 wherein the inhibitor is an antisense oligonucleotide corresponding to HNOEL-iso polynucleotide.

47. (New) A pharmaceutical composition for the treatment of fibrosis related pathology comprising as an active ingredient an inhibitor which inhibits production of HNOEL-iso polypeptide together with a pharmaceutically acceptable carrier.

48. (New) The pharmaceutical composition of claim 47 wherein the fibrosis related pathology is selected from liver fibrosis, pulmonary fibrosis and cardiac fibrosis.

49. (New) The pharmaceutical composition of claim 47 wherein the fibrosis related pathology is kidney fibrosis.

50. (New) The pharmaceutical composition of claim 47 wherein the fibrosis related pathology is scarring.

51. (New) The pharmaceutical composition of claim 47 wherein the fibrosis related pathology is selected from nephropathy, in particular diabetic nephropathy, chronic renal insufficiency, chronic renal failure and glomerulosclerosis.

52. (New) The pharmaceutical composition of claim 47 wherein the inhibitor is an antibody which binds specifically to HNOEL-iso polypeptide.

53. (New) The pharmaceutical composition of claim 47 wherein the inhibitor is an siRNA which is specific to HNOEL-iso polynucleotide.

54. (New) The pharmaceutical composition of claim 47 wherein the inhibitor is an antisense oligonucleotide corresponding to HNOEL-iso polynucleotide.

55. (New) A method for the treatment of disease selected from osteoarthritis, osteoporosis, other bone disease and cardiovascular disease in a subject in need of such treatment comprising administering to the subject an amount of an inhibitor of HNOEL-iso polypeptide sufficient to effect a substantial inhibition of the HNOEL-iso polypeptide so as to thereby treat the subject.